Could a smarter chemo schedule help kids beat cancer?

NCT ID NCT01760226

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a chemotherapy regimen called DA-EPOCH-R in 4 children with certain B-cell cancers (DLBCL, PMBCL, or PTLD). The drugs are given as a continuous infusion over several days, and doses are adjusted based on how the child's body handles them. The goal was to see if this approach is safe and could improve cure rates while reducing side effects, as it has in adults.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
DA-EPOCH-R (a combination of rituximab, etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone, and G-CSF)
What this could lead to
If this approach works in children, it could offer a safer and more effective treatment for certain B-cell cancers, potentially reducing side effects while maintaining high cure rates.
What could go wrong
This is a very early, small study with only 4 participants, so results may not apply to all children. The safety and effectiveness in children are still unknown, and there are risks from chemotherapy like infections and mouth sores.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.